Association of biochemically verified post-diagnosis smoking and nonmuscle-invasive bladder cancer recurrence risk Journal Article
| Authors: | Furberg, H.; Petruzella, S.; Whiting, K.; Stein, E.; Orlow, I.; Kenney, J.; Corrales-Guerrero, S.; Benfante, N.; Cha, E. K.; Donahue, T. F.; Donat, S. M.; Herr, H. W.; Matulewicz, R. S.; Pietzak, E.; Dalbagni, G.; Ostroff, J.; Bochner, B. H. |
| Article Title: | Association of biochemically verified post-diagnosis smoking and nonmuscle-invasive bladder cancer recurrence risk |
| Abstract: | PURPOSE: Our goal was to determine the association between biochemically verified post-diagnosis smoking exposure and nonmuscle-invasive bladder cancer (NMIBC) recurrence risk. MATERIALS AND METHODS: We conducted a prospective study of 354 NMIBC patients with a smoking history undergoing care between 2015 and 2018. Patients contributed at least 2 biospecimens during followup which were tested for cotinine to determine biochemically verified post-diagnosis smoking exposure (yes/no). Our primary endpoint was time to first recurrence after study start date. We examined whether post-diagnosis smoking exposure was associated with recurrence risk in multivariable Cox proportional hazards models that accounted for demographics, clinicopathological variables, time since diagnosis and pack-years. RESULTS: Patients were predominantly White, male and had a median age of 68 years. Most patients had Ta disease (62%) and tumors of high grade (68%). Intravesical bacillus Calmette-Guérin was given to 63% of the cohort. Patients were followed for a median of 3.6 years since study start. Post-diagnosis smoking exposure was detected in 22% of patients, and 38.7% (137) of patients experienced a recurrence during followup. In multivariable models, only bacillus Calmette-Guérin treatment and prior recurrence rate were significantly associated with recurrence. There was no association between post-diagnosis smoking exposure and recurrence risk (HR: 0.73, 95% CI: 0.45-1.20). CONCLUSIONS: In a cohort of patients with predominantly high risk NMIBC, post-diagnosis smoking exposure was not associated with NMIBC recurrence. However, smoking cessation support remains a critical component of cancer care given that the benefits of quitting extend far beyond NMIBC recurrence. |
| Keywords: | aged; prospective study; prospective studies; bcg vaccine; neoplasm recurrence, local; smoking; pathology; bladder tumor; urinary bladder neoplasms; tumor recurrence; mycobacterium bovis; immunological adjuvant; neoplasm invasiveness; epidemiology; adjuvants, immunologic; administration, intravesical; intravesical drug administration; adverse event; tumor invasion; cotinine; humans; human; male; female |
| Journal Title: | Journal of Urology |
| Volume: | 207 |
| Issue: | 6 |
| ISSN: | 0022-5347 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2022-06-01 |
| Start Page: | 1200 |
| End Page: | 1206 |
| Language: | English |
| DOI: | 10.1097/ju.0000000000002449 |
| PUBMED: | 35084998 |
| PROVIDER: | scopus |
| PMCID: | PMC9472323 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work